TMB and MSI are reported biomarkers that can predict TME status and anti-tumor efficacy of ICI therapy [44], and used Spearman’s correlation analysis to test the correlations of TMB and MSI with TAP1 expression. This evidence concerns the gene TAP1 and neoplasm.